DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for stiff skin syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleStiff skin syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for stiff skin syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibrillin 1 (FBN1) — FBN1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1UZK · 1.35 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
No abstract in this set reports a drug repurposing trial for stiff skin syndrome. The 2019 review discusses repurposing drugs for skin cancer, not for stiff skin syndrome. The 2020 case report of a 9-year-old patient states that therapeutic options for stiff skin syndrome are scarce and ineffective, and recommends early physical therapy. The 2023 reviews describe stiff skin syndrome as a rare connective tissue disease with progressive skin stiffness and limited joint mobility, and mention emerging therapies being developed, but provide no concrete drug names, response rates, or survival data. The 2009 review describes 6 new cases and 31 from the literature, but gives no drug treatment results.
There are no numbers from any controlled trial to report. The only concrete clinical recommendation across these abstracts is early physical therapy to prevent complications. No abstract claims efficacy for any drug in stiff skin syndrome.
What is missing is any funded clinical trial testing a repurposed drug in this disease, any validated patient stratification method, and any quantitative outcome data from a treated cohort.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Dermatology · 1985 · 27 citations
Stiff Skin Syndrome
AbstractStiff skin syndrome was first documented by Esterly and McKusick. We saw a patient with this disease, as well as another who had a similar condition but a somewhat different histology. These two patients shared heritable stiff skin, restricted joint mobility, and absent mucopolysacchariduria. In stiff skin syndrome, which may have two variants, skin biopsy demonstrates large cells stained metachromatically by toluidine blue. These cells are shaped like dermal melanocytes or rounded cells and their presence may be directly related to the deposition of mucopolysaccharide in the dermis. In some cases they may invade the deeper tissues. Two cases of stiff skin syndrome that were in the Japanese literature are also discussed.
AbstractDrug repurposing is the process of developing existing or abandoned drugs for a different disease. Repurposing can circumvent higher costs and times associated with conventional drug discovery strategies because toxicity and pharmacokinetics profiles are typically already established. This brief review focuses on efforts to repurpose drugs for skin cancer and includes reuse of antihypertensives, anthelmintics and antifungals among a range of other medicines. Repurposing not only ushers promising known drugs for new indications, the process of repurposing can uncover new mechanistic insights in the pathogenesis of disease and uncover new opportunities for pharmaceutical intervention.
Archivos Argentinos de Pediatria · 2020 · 3 citations · open access
Síndrome de piel indurada en un paciente pediátrico: un desafío terapéutico. Presentación de un caso
AbstractStiff skin syndrome is a chronic, rare sclerosing disorder that occurs in childhood, characterized by progressive induration of the skin that can cause thoracic restrictions and respiratory distress, limitations in joint mobility and gait difficulties, with significant deterioration of the quality of life. Because their therapeutic options are scarce and ineffective it is essential to start an early physical therapy to prevent these complications and to continue studying this condition to be able to offer patients more and better treatments. We present the case of a 9-year-old patient with indurated skin syndrome and its therapeutic challenge.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 1 citations · open access
Stiff Skin Syndrome: Clinical Exploration, Pathophysiology and Therapeutic Advances in a Rare Connective Tissue Disease
AbstractStiff Skin Syndrome, also known as "diffuse stiff skin syndrome" or "Scleroderma-like syndrome with focal contracture", is a rare and complex clinical entity in the spectrum of connective tissue diseases. This disorder is characterized by progressive and diffuse infiltration of connective tissue into the skin and underlying tissues, resulting in extreme skin stiffness and limited joint mobility. In addition to its cutaneous and joint manifestations, stiff skin syndrome can affect multiple internal organs, making it a clinical entity of great multidisciplinary relevance. This article aims to provide a comprehensive review of stiff skin syndrome, addressing its epidemiology, clinical manifestations, etiopathogenesis, differential diagnosis, and current therapeutic options. Recent research that has shed light on the underlying molecular mechanisms and emerging therapies that are being developed to improve the quality of life of patients affected by this disease are highlighted. In addition, the importance of a comprehensive evaluation and an interdisciplinary therapeutic approach to optimize the clinical management of individuals with rigid skin syndrome is highlighted.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Stiff Skin Syndrome: Clinical Exploration, Pathophysiology and Therapeutic Advances in a Rare Connective Tissue Disease
AbstractStiff Skin Syndrome, also known as "diffuse stiff skin syndrome" or "Scleroderma-like syndrome with focal contracture", is a rare and complex clinical entity in the spectrum of connective tissue diseases. This disorder is characterized by progressive and diffuse infiltration of connective tissue into the skin and underlying tissues, resulting in extreme skin stiffness and limited joint mobility. In addition to its cutaneous and joint manifestations, stiff skin syndrome can affect multiple internal organs, making it a clinical entity of great multidisciplinary relevance. This article aims to provide a comprehensive review of stiff skin syndrome, addressing its epidemiology, clinical manifestations, etiopathogenesis, differential diagnosis, and current therapeutic options. Recent research that has shed light on the underlying molecular mechanisms and emerging therapies that are being developed to improve the quality of life of patients affected by this disease are highlighted. In addition, the importance of a comprehensive evaluation and an interdisciplinary therapeutic approach to optimize the clinical management of individuals with rigid skin syndrome is highlighted.
AbstractStiff skin syndrome (SSS) is a rare disorder characterized by progressive rock-hard induration of the skin. In this review, the authors describe 6 previously unreported cases and summarize findings in these patients and in an additional 31 from the literature.
They describe a typical presentation in infancy or early childhood of insidious skin hardening with well-demarcated, rock-hard …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
